openPR Logo
Press release

Hepatitis C Treatment Market 2024 | Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson & Johnson,

11-27-2018 08:12 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Research Report Insights

Hepatitis C Treatment Market 2024 | Hoffmann-La Roche Ltd,

Demand for Hepatitis C Treatment Expected to Remain High in North America during 2016-2024

According to a recent study conducted by RRI, the global market for hepatitis C treatment is expected to expand at a CAGR of over 13% during the forecast period (2016-2024). By the end of 2016, market is anticipated to stand at US$ 26.6 and is estimated to surpass US$ 71 Billion by 2024.

Request For Report Sample: https://www.researchreportinsights.com/report/sample/110114958/Hepatitis-C-Treatment-Market

Factors such as higher per capita healthcare expenditure worldwide and growing prevalence of hepatitis C infections in countries such as U.S. and Canada is expected to drive the global market for global hepatitis C treatment during the forecast period. Moreover, increasing awareness campaigns by private NGPOs and encouraging government initiatives to limit infection is also supporting the market growth. On the other hand, expensive drugs for hepatitis C treatment and lack of awareness about hepatitis C infection amongst the people in developing regions across the globe may inhibit the growth of the market during the forecast period.

On the basis of drugs, the global market for hepatitis C treatment has been segmented into HCV NS5A inhibitors, HCV protease inhibitors, interferon & antiviral, HCV polymerase inhibitors, and combination therapy. Amongst these, combination therapy is expected to be the largest, accounting for the highest share of the market. The segment is expected to expand at a CAGR of over 13% during 2016-2024.

On the basis distribution channel, the market has been segmented into online pharmacies, hospital pharmacies and retail pharmacies. Hospital pharmacy is expected to be the most dominant segment during the forecast period. By 2024, the segment is anticipated to account for over 43% share of the market in terms of revenue. Due to increasing occurrence of hospitalization and improved services and accessibility, demand for the segment is expected to grow higher in the near future.

On the other hand, the online pharmacies segment is anticipated to witness the highest CAGR over the forecast period. The growth of the segment is due to ample stock of hepatitis C treatment drugs with added discount offered by online drug pharmacies.

On the basis of region, North America is expected to be the leading market for hepatitis C treatment, estimated to account for 45% share by the end of 2016. Whereas, the market in Asia Pacific is anticipated to expand at an overwhelming CAGR of over 14%. By 2016, Europe is estimated to contribute over 19% share to the global market for hepatitis C treatment. The market in Latin America is expected to witness a sound growth, which was estimated at US$ 2,915.8 Million in 2015 and is expected to surpass US$ 3,311 by 2016 year end. In 2015, the market in the Middle East and Africa (MEA) region stood at US$ 1,792.5 Million and is anticipated to cross US$ 1,988 Million by the end of 2016.

Request Report Discount: https://www.researchreportinsights.com/report/discount/110114958/Hepatitis-C-Treatment-Market

Vendor News
Key participants operating in the global market for hepatitis C treatment include F Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc., AbbVie Inc., and Kadmon Holdings, Inc. Most of these companies are actively focusing on partnering with healthcare solutions and service providers in order to offer better patient treatment and enhance operational efficiency.

Summary: The global market for hepatitis C treatment expected to grow at a pronounced rate.

Report Analysis: https://www.researchreportinsights.com/report/rd/110114958/Hepatitis-C-Treatment-Market

Research Report Insights (RRI) is a leading market intelligence and consulting firm. We deliver a host of services including custom research reports, syndicated research reports, and consulting services which are personalised in nature. RRI delivers a complete packaged solution to clients; this combines current market intelligence, technology inputs, statistical anecdotes, valuable growth insights, 360-degree view of the competitive framework, and anticipated market trends.

Contact Us:
Research Report Insights (RRI)
42 Joseph Street
Port carling P0B 1J0
Muskoka, Ontario1
Phone - +1-631-721-4201
Website: https://www.researchreportinsights.com/
Email: sales@researchreportinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hepatitis C Treatment Market 2024 | Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson & Johnson, here

News-ID: 1403094 • Views:

More Releases from Research Report Insights

Automotive Brake System Market 5.7% of CAGR throughout 2017-2022 Research Report Insights
Automotive Brake System Market 5.7% of CAGR throughout 2017-2022 Research Report …
The global automotive brake system market is anticipated to witnessing a substantial growth due to fresh prospects of the automotive industry in emerging along with developing economies and increased safety concerns by the government. It was stated in the report that the overall growth of the market is expected to reach a market value of above US$ 25 Billion through 2022, exhibiting a strong 5.7% of CAGR throughout 2017-2022. In modern
Automotive Brake System Market 2022 | Continental AG, Robert Bosch GmbH, Wabco Holdings, Inc., ZF Friedrichshafen AG, Aisin Seiki Co, Ltd., Knorr-Bremse AG, Akebono Brake Industry Co. Ltd
Automotive Brake System Market 2022 | Continental AG, Robert Bosch GmbH, Wabco H …
The global automotive brake system market is anticipated to witnessing a substantial growth due to fresh prospects of the automotive industry in emerging along with developing economies and increased safety concerns by the government. It was stated in the report that the overall growth of the market is expected to reach a market value of above US$ 25 Billion through 2022, exhibiting a strong 5.7% of CAGR throughout 2017-2022. In modern
Tarpaulin Sheets Market These factors, thus, are likely to boost the plastic mar …
A tarpaulin is a big sheet of water-proof material available in various sizes, generally being crafted from plastic like HDPE, LDPE. Tarps can be used to refuge any kind of items. Tarpaulins can efficiently be used to cover goods in the course of shipping and then they also can be used to house goods internal of a truck body so they are not uncovered to the elements. The Tarpaulin Sheets Market
Research Report Insights present kayaks market by 21 percent, or over by $42 mil …
Kayaking is a watersport which involves paddling using a double-bladed oar and a small boat known as a kayak. The boats come in a variety of sizes and types, depending on their intended use, but most kayaks feature an enclosed deck which covers the legs. The boat sits low in the water & usually only accommodates the single paddler, but tandem kayaks hold two people and some boats hold three

All 5 Releases


More Releases for Hepatitis

Is Hepatitis A Vaccine Required?
Hepatitis A Vaccine Market describes its growth, size, share, Forecast and trends to 2025 Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year. Two types of HAV vaccines are currently available internationally: 1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available
Hepatitis Drugs Market Is Growing Due to Increasing R&D Investments on Hepatitis …
The global hepatitis drugs market is growing due to increasing incidences of hepatitis and increasing support from government organizations. In addition, the growing geriatric population, and increasing R&D investments on hepatitis research and drug discovery are also driving the growth of the global hepatitis drugs market. Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/hepatitis-drugs-market Among the various types, the hepatitis C segment is expected to be the largest segment, and expected to witness the fastest
Hepatitis B Therapeutics Market Is Driven by Rising Incidence of Hepatitis B In …
Hepatitis B is a life threatening liver infection caused by hepatitis B virus. Adults who get affected by hepatitis B virus for a short time and then get cured is known as acute hepatitis B. Infection that lasts for a long time is known as chronic hepatitis B. Vaccine is the most preferred choice of doctors and physicians to protect people from the disease. The vaccine prevents the infection and
Hepatitis E Hyperendemicity to Drive Hepatitis E Diagnostic Tests Market Growth
Global Hepatitis E Diagnostic Tests Market: Snapshot The growing incidence of hepatitis E, a liver disease caused by infection due to the virus hepatitis E virus (HEV), is a leading cause of morbidity and mortality worldwide. There is increasing prevalence of hepatitis E in resource-limited region, such as various countries of Asia Pacific. The people of these regions suffer with frequent water contamination and have limited access to sanitation and hygiene,
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Hepatitis C Drug Pipeline Analysis
“Hepatitis C Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Hepatitis C. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each